secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-068759
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adverum restates 2022-2024 financials on lease accounting errors; subtenant in default
--------------------------------------------------------------------------------

- Non-cash errors in accounting for tenant improvement allowances on NC lease/sublease; restating 2022 and 2023 annual and 2023/2024 quarterly statements.
- Expects at least one material weakness in internal control over financial reporting.
- Subtenant Advanced Medical Partners (and Jaguar Gene Therapy) in default under sublease; company remains obligated under operating lease.
- Cash, equivalents, and short-term investments expected to fund operations into second half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525068759/0001193125-25-068759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525068759/d848903d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-068759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer